ClinPlan provides automated, efficient, and accurate way to assess and reassess trial expenses over time throughout the life of the trial.
DURHAM, NC - February 9, 2015 - Clinverse, Inc., provider of automated financial management technology solutions for clinical trials, announced today that it has expanded its suite of products with the addition of ClinPlan™, purpose-built software for clinical trial budget management and forecasting.
“Changes in the clinical trial environment today, such as complex study designs and an increasing need to use outsourced vendors, have resulted in significant challenges for effective financial management of trial budgets and forecasting,” says Denis Connaghan, Clinverse CEO. “But for more than 70% of companies, the primary tool continues to be Microsoft Excel. These spreadsheets are already difficult to share and consolidate with other financial forecasting and budgeting data, don’t help forecast subject and site activation, take too long to update, and are prone to error. With ClinPlan, our clients can automate the process of developing a full forecasted expense picture on a routine basis and set the stage for decreasing the variance in expected funds requests.”
ClinPlan provides clients with the ability to consolidate budgets from the variety of vendors and sources that contribute to the total trial expense. The solution also imports site activation data and schedule of assessments and related expenses to allow the cost over time to be evaluated and reevaluated using actual data once the trial begins. The result is better cash management as sponsors and CROs can assess trial expense needs based on site and subject enrollment to understand when trial expenses will be incurred over time due the myriad of changes and proactively plan for funds necessary to support the ongoing expense needs of the trial.
Key features of ClinPlan include the ability to:
Both CROs and sponsors benefit from ClinPlan-CROs receive an accurate picture of future expense needs based on trial performance in order to make more accurate fund requests from sponsors, while sponsors receive an accurate reflection of when total budget expenses will occur in future months, quarters, and years.
“ClinPlan is the first of three new products we have coming down the pipeline this year,” said Connaghan. “We work hard to stay in front of what’s happening in the industry and provide best-in-class solutions for every financial aspect of a clinical trial to set our clients up for success. Not only do our solutions improve time, cost, and resource efficiencies, but they also provide sponsors and CROs a higher level of confidence as they move forward with the next phase of their clinical trial.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.